← Leaderboards
Mohamed Seleem
Purdue University
$7,254,657
Attributed
$8,487,674
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2015–23$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,487,674 · 5
By mechanism
R01$7,836,896 · 3
R56$376,278 · 1
R41$274,500 · 1
Top collaborators
- Ji-Xin Cheng4 shared
- Richard John Suderman1 shared
Others in their field
Top investigators on “United States”
- Leonard Freedman · Leidos Biomedical Research, Inc.$818,172,357
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$638,373,375
- David Heimbrook · Leidos Biomedical Research, Inc.$632,657,800
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United StatesResistanceInfectionMortalityPharmaceutical PreparationsPathogenAntimicrobialDrug DiscoveryInnovationLeadDoseCessation Of LifeCostAntibioticsAnti-Bacterial AgentsRouteAnimal ModelBacteriaDrug KineticsIn VitroFda ApprovedMulti-Drug ResistanceMouse ModelHealth Care Costs
Grant awards (18)
Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococci$608,362
R01 · FY2023 · AI · contact PI
Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B$274,500
R41 · FY2023 · AI
Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococci$619,644
R01 · FY2022 · AI · contact PI
Metabolic Assessment of Anti-Microbial Susceptibility within One Cell Cycle$518,480
R01 · FY2022 · AI
Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococci$645,971
R01 · FY2021 · AI · contact PI
Metabolic Assessment of Anti-Microbial Susceptibility within One Cell Cycle$518,480
R01 · FY2021 · AI
Repurposing auranofin and ebselen for treatment of multidrug resistant pathogens$460,295
R01 · FY2021 · AI · contact PI
Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococci$620,749
R01 · FY2020 · AI · contact PI
Metabolic Assessment of Anti-Microbial Susceptibility within One Cell Cycle$590,895
R01 · FY2020 · AI
Repurposing auranofin and ebselen for treatment of multidrug resistant pathogens$321,417
R01 · FY2020 · AI · contact PI
Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococci$130,566
R01 · FY2020 · AI · contact PI
Repurposing auranofin and ebselen for treatment of multidrug resistant pathogens$130,479
R01 · FY2020 · AI · contact PI
Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococci$751,315
R01 · FY2019 · AI · contact PI
Metabolic Assessment of Anti-Microbial Susceptibility within One Cell Cycle$563,680
R01 · FY2019 · AI
Repurposing auranofin and ebselen for treatment of multidrug resistant pathogens$446,984
R01 · FY2019 · AI · contact PI
Repurposing auranofin and ebselen for treatment of multidrug resistant pathogens$447,761
R01 · FY2018 · AI · contact PI
Repurposing auranofin and ebselen for treatment of multidrug resistant pathogens$461,818
R01 · FY2017 · AI · contact PI
Repurposing auranofin as antimicrobial to treat staphylococcal infections$376,278
R56 · FY2015 · AI · contact PI